3SBio Yönetim

Yönetim kriter kontrolleri 4/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Jing Lou

İcra Kurulu Başkanı

CN¥4.9m

Toplam tazminat

CEO maaş yüzdesi	26.2%
CEO görev süresi	18.7yrs
CEO sahipliği	2.4%
Yönetim ortalama görev süresi	3.8yrs
Yönetim Kurulu ortalama görev süresi	6.9yrs

Son yönetim güncellemeleri

Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being

Jun 19

Recent updates

Solid Earnings Reflect 3SBio's (HKG:1530) Strength As A Business

May 07

3SBio Inc. (HKG:1530) Stock Rockets 36% As Investors Are Less Pessimistic Than Expected

Apr 24

3SBio (HKG:1530) Has Announced A Dividend Of CN¥0.25

Apr 17

3SBio (HKG:1530) Will Pay A Dividend Of CN¥0.25

Mar 31

3SBio Inc. (HKG:1530) Released Earnings Last Week And Analysts Lifted Their Price Target To HK$10.80

Mar 30

3SBio Inc. (HKG:1530) Soars 27% But It's A Story Of Risk Vs Reward

Mar 10

3SBio Inc. (HKG:1530) Screens Well But There Might Be A Catch

Jan 17

3SBio's (HKG:1530) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Oct 08

3SBio Inc.'s (HKG:1530) P/E Is Still On The Mark Following 34% Share Price Bounce

Oct 07

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Sep 26

Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being

Jun 19

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued

Nov 21

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Sep 10

3SBio Inc. (HKG:1530) Shares Could Be 38% Below Their Intrinsic Value Estimate

Aug 22

3SBio Inc.'s (HKG:1530) Intrinsic Value Is Potentially 48% Above Its Share Price

May 21

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

Apr 16

CEO Tazminat Analizi

Jing Lou'un ücretlendirmesi 3SBio'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Dec 31 2024	n/a	n/a	CN¥2b
Sep 30 2024	n/a	n/a	CN¥2b
Jun 30 2024	n/a	n/a	CN¥2b
Mar 31 2024	n/a	n/a	CN¥2b
Dec 31 2023	CN¥5m	CN¥1m	CN¥2b
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥2b
Dec 31 2022	CN¥4m	CN¥1m	CN¥2b
Sep 30 2022	n/a	n/a	CN¥2b
Jun 30 2022	n/a	n/a	CN¥2b
Mar 31 2022	n/a	n/a	CN¥2b
Dec 31 2021	CN¥4m	CN¥932k	CN¥2b
Sep 30 2021	n/a	n/a	CN¥1b
Jun 30 2021	n/a	n/a	CN¥1b
Mar 31 2021	n/a	n/a	CN¥934m
Dec 31 2020	CN¥4m	CN¥432k	CN¥836m
Sep 30 2020	n/a	n/a	CN¥1b
Jun 30 2020	n/a	n/a	CN¥1b
Mar 31 2020	n/a	n/a	CN¥1b
Dec 31 2019	CN¥194m	CN¥432k	CN¥974m
Sep 30 2019	n/a	n/a	CN¥1b
Jun 30 2019	n/a	n/a	CN¥1b
Mar 31 2019	n/a	n/a	CN¥1b
Dec 31 2018	CN¥6m	CN¥432k	CN¥1b

Tazminat ve Piyasa: Jing 'ın toplam tazminatı ($USD 676.52K ) Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 537.52K ).

Tazminat ve Kazançlar: Jing 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Jing Lou (61 yo)

18.7yrs

Görev süresi

CN¥4,896,000

Tazminat

Dr. Jing Lou, M.D., Ph.D. is a Co-Founder of 3SBio Inc. and has been its Executive Chairman of the Board since April 1, 2012 and also serves as its Chief Executive Officer and President. Dr. Lou is Directo...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Dongmei Su	Senior VP & Executive Director	no data	CN¥1.46m	1.03% HK$ 294.6m
Jing Lou	Co-Founder	no data	CN¥4.90m	2.4% HK$ 682.1m
Xiang He	Chief Financial Officer	1.8yrs	Veri yok	Veri yok
Siu Kuen Lai	Company Secretary	3.3yrs	Veri yok	Veri yok
Yanli Liu	General Manager of Sunshine Guojian Pharmaceutical (Shanghai) Co.	1.7yrs	Veri yok	Veri yok
Yong Xu	General Manager of Shenzhen Sciprogen Bio-pharmaceutical Technology Co.	10.3yrs	Veri yok	Veri yok
Zheng Jin	General Manager of Shenyang Sunshine Pharmaceutical Co.	4.3yrs	Veri yok	Veri yok
An Yu	General Manager of Zhejiang Sunshine Mandi Pharmaceutical Co.	4.3yrs	Veri yok	Veri yok
Zhao Xinyi	Executive of IR	no data	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

45.5yo

Ortalama Yaş

Deneyimli Yönetim: 1530 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Dongmei Su	Senior VP & Executive Director	12.9yrs	CN¥1.46m	1.03% HK$ 294.6m
Jing Lou	Co-Founder	18.7yrs	CN¥4.90m	2.4% HK$ 682.1m
Tianruo Pu	Independent Non-Executive Director	9.9yrs	CN¥274.00k	Veri yok
Jiaoe Zhang	Non-Executive Director	less than a year	CN¥406.00k	0.52% HK$ 148.6m
Hoi Ti Yang	Independent Non-Executive Director	3.9yrs	CN¥274.00k	Veri yok
Joo Yeow Ng	Independent Non-Executive Director	3.3yrs	CN¥274.00k	Veri yok

6.9yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 1530 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.9 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/05/10 02:21
Gün Sonu Hisse Fiyatı	2025/05/09 00:00
Kazançlar	2024/12/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

3SBio Inc. 34 Bu analistlerden 12, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Difei Yang	Capstone Investments
Bo Yu	China International Capital Corporation Limited
Zhuhong Chen	China Merchants Securities (HK) Co., Ltd

3SBio Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Non-Executive Director recently sold HK$1.4m worth of stock

Non-Executive Director recently sold HK$5.7m worth of stock

3SBio Inc., Annual General Meeting, Jun 25, 2025

Co-Founder recently bought HK$1.5m worth of stock

Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being

3Sbio Inc. Announces Management Changes

Recent updates

Solid Earnings Reflect 3SBio's (HKG:1530) Strength As A Business

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Non-Executive Director recently sold HK$1.4m worth of stock

3SBio Inc. (HKG:1530) Stock Rockets 36% As Investors Are Less Pessimistic Than Expected

Non-Executive Director recently sold HK$5.7m worth of stock

3SBio (HKG:1530) Has Announced A Dividend Of CN¥0.25

3SBio Inc. Receives Breakthrough Therapy Designation by China's National Medical Products Administration

New minor risk - Share price stability

Investor sentiment improves as stock rises 33%

3SBio (HKG:1530) Will Pay A Dividend Of CN¥0.25

3SBio Inc. (HKG:1530) Released Earnings Last Week And Analysts Lifted Their Price Target To HK$10.80

Dividend of HK$0.25 announced

Full year 2024 earnings: EPS and revenues exceed analyst expectations

3SBio Inc., Annual General Meeting, Jun 25, 2025

Investor sentiment improves as stock rises 18%

3SBio Inc. (HKG:1530) Soars 27% But It's A Story Of Risk Vs Reward

3SBio Inc. to Report Fiscal Year 2024 Results on Mar 25, 2025

3SBio Inc. (HKG:1530) Screens Well But There Might Be A Catch

Investor sentiment deteriorates as stock falls 17%

3SBio's (HKG:1530) Sluggish Earnings Might Be Just The Beginning Of Its Problems

3SBio Inc.'s (HKG:1530) P/E Is Still On The Mark Following 34% Share Price Bounce

First half 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 22%

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Co-Founder recently bought HK$1.5m worth of stock

First half 2024 earnings: EPS and revenues exceed analyst expectations

3SBio Inc. to Report First Half, 2024 Results on Aug 22, 2024

Upcoming dividend of HK$0.25 per share

Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being

There's Reason For Concern Over 3SBio Inc.'s (HKG:1530) Price

3Sbio Inc. Announces Management Changes

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

New minor risk - Dividend sustainability

3SBio Inc., Annual General Meeting, Jun 25, 2024

3SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

Pinning Down 3SBio Inc.'s (HKG:1530) P/E Is Difficult Right Now

Mandi Foam of 3SBio Inc. Approves for Market Launch

These 4 Measures Indicate That 3SBio (HKG:1530) Is Using Debt Safely

Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?

First half 2023 earnings: EPS and revenues exceed analyst expectations

Is 3SBio (HKG:1530) A Risky Investment?

First half 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.39 in 1H 2022)

3SBio Inc. to Report First Half, 2023 Results on Aug 24, 2023

Calculating The Fair Value Of 3SBio Inc. (HKG:1530)

3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer

With EPS Growth And More, 3SBio (HKG:1530) Makes An Interesting Case

3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market

Upcoming dividend of HK$0.10 per share at 1.3% yield

3SBio Inc., Annual General Meeting, Jun 20, 2023

3SBio (HKG:1530) Has A Pretty Healthy Balance Sheet

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?

Now 22% undervalued

Is 3SBio Inc. (HKG:1530) Trading At A 23% Discount?

3SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director

Do 3SBio's (HKG:1530) Earnings Warrant Your Attention?

Less than half of directors are independent

Investor sentiment improved over the past week

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Investor sentiment improved over the past week

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

3SBio Inc. (HKG:1530) Shares Could Be 49% Below Their Intrinsic Value Estimate

First half 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.35 in 1H 2021)

Upcoming dividend of HK$0.20 per share

Full year 2021 earnings: EPS exceeds analyst expectations

Less than half of directors are independent

Is 3SBio Inc. (HKG:1530) Trading At A 45% Discount?

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Full year 2021 earnings: EPS exceeds analyst expectations